Parkinson's Disease Treatment Options

Parkinson's Disease Treatment Options

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkinson's Disease Treatment Options</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>alpha-synuclein</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">ACI-7104</td>
<td>alpha-synuclein vaccine</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCase</td>
</tr>
</table>

Parkinson's Disease Treatment Options

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Parkinson's Disease Treatment Options</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>alpha-synuclein</td>
</tr>
<tr>
<td class="label">BIIB122 (DNL151)</td>
<td>LRRK2</td>
</tr>
<tr>
<td class="label">ACI-7104</td>
<td>alpha-synuclein vaccine</td>
</tr>
<tr>
<td class="label">Venglustat</td>
<td>GCase</td>
</tr>
</table>

[Parkinson's disease](/diseases/parkinsons-disease) (PD) is a progressive neurodegenerative disorder affecting approximately 6-10 million people globally["@pablo2024"]. The disease results from the loss of dopaminergic neurons in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta, leading to characteristic motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability["@kalia2015"]. Non-motor symptoms such as sleep disorders, autonomic dysfunction, cognitive impairment, and psychiatric manifestations are also common and significantly impact quality of life["@jankovic2008"].

Modern PD treatment encompasses symptomatic management, complication prevention, and emerging disease-modifying therapies. This guide provides an overview of the comprehensive treatment landscape.

Pharmacological Treatments

Levodopa

[Levodopa](/therapeutics/levodopa-therapy) remains the gold standard for PD treatment[@fahn2005]. As the dopamine precursor, it effectively controls motor symptoms but long-term use leads to motor complications.

Key formulations:

• Carbidopa/levodopa (Sinemet) - immediate and controlled-release
• Carbidopa/levodopa/entacapone (Stalevo) - extended effect
• Duodopa intestinal gel - continuous infusion for advanced disease[@brooks2014]
• Subcutaneous levodopa - emerging delivery systems

Dopamine Agonists

[Dopamine agonists](/therapeutics/dopamine-agonists) provide symptomatic relief by directly stimulating dopamine receptors[@schapira2019].

Oral options:

• Pramipexole: D2/D3 agonist, 1.5-4.5 mg/day[@hubble2000]
• Ropinirole: D2/D3 agonist, 3-8 mg/day[@adler2004]
• Rotigotine: Transdermal patch, 2-8 mg/24h

MAO-B Inhibitors

[MAO-B inhibitors](/therapeutics/mao-b-inhibitors-parkinsons) extend dopamine availability by blocking its enzymatic breakdown[@riederer2011].

• Selegiline: 5-10 mg/day
• Rasagiline: 1 mg/day[@olanow2009]
• Safinamide: 50-100 mg/day[@schapira2017]

COMT Inhibitors

COMT inhibitors prolong levodopa effect by blocking peripheral metabolism[@antonini2016].

• Entacapone: 200 mg with each levodopa dose
• Opicapone: 50 mg once daily[@ferreira2016]
• Tolcapone: 100-200 mg TID (requires liver monitoring)

Amantadine

Provides modest benefit and uniquely reduces levodopa-induced dyskinesias.

Surgical Therapies

Deep Brain Stimulation

[Deep brain stimulation](/treatments/deep-brain-stimulation) (DBS) is highly effective for advanced PD[@krack2003].

Targets: Subthalamic nucleus (STN) or Globus pallidus interna (GPi)[@volkmann2010]

Outcomes[@weaver2009]:

• 50-70% motor improvement
• 50-80% reduction in "off" time
• 50-70% dyskinesia reduction

Other Procedures

• Pallidotomy for dyskinesia control
• Thalamotomy for tremor
• Focused ultrasound for non-invasive lesioning

Disease-Modifying Therapies

Under Investigation

Therapeutic Targets

• α-synuclein aggregation inhibitors and immunotherapies
• LRRK2 kinase inhibitors for genetic PD
• GBA modulators for GBA-associated PD

Non-Motor Symptom Management

Sleep Disorders

• REM sleep behavior disorder: Melatonin or clonazepam
• Excessive daytime sleepiness: Modafinil, sleep hygiene

Psychiatric Symptoms

• Depression: SSRIs, SNRIs
• Psychosis: Pimavanserin, quetiapine, clozapine

Autonomic Issues

• Orthostatic hypotension: Fludrocortisone, midodrine
• Constipation: Fiber, PEG, prokinetics

Lifestyle Interventions

Exercise

• 150 min/week moderate aerobic activity
• Balance training (Tai Chi, dance)
• Strength training 2-3x weekly[@jankovic2020]

Nutrition

• Mediterranean diet may slow progression
• Even protein distribution with levodopa dosing
• Adequate vitamin D and calcium

Complementary Therapies

• Acupuncture: Emerging evidence supports acupuncture as adjunctive therapy for motor symptoms, with meta-analyses showing improvements in UPDRS scores. May also benefit non-motor symptoms including sleep and mood. See [Acupuncture Therapy for Parkinson's Disease](/therapeutics/acupuncture-parkinsons-disease)[@wang2020pd]

Comprehensive Resources

For detailed information on treatment protocols, see the full [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment) page.

Conclusion

PD treatment has advanced significantly with multiple therapeutic options. [Levodopa](/therapeutics/levodopa-therapy) remains foundational, complemented by [dopamine agonists](/therapeutics/dopamine-agonists), [MAO-B inhibitors](/therapeutics/mao-b-inhibitors-parkinsons), and [surgical interventions](/treatments/deep-brain-stimulation). Disease-modifying therapies targeting α-synuclein and LRRK2 offer future promise.

References

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Levodopa Therapy](/therapeutics/levodopa-therapy)
• [Dopamine Agonists](/therapeutics/dopamine-agonists)
• [Deep Brain Stimulation](/treatments/deep-brain-stimulation)
• [Acupuncture Therapy for Parkinson's Disease](/therapeutics/acupuncture-parkinsons-disease)